Konstantinopoulos, P. A. et al. (2022) EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncology, 18(31), pp. 3481-3492. (doi: 10.2217/fon-2022-0666) (PMID:36066851)
Text
278801.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 2MB |
Abstract
Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non-BRCA-mutated ovarian cancer. Here, we describe the study design and rationale for the phase III, multicenter, open-label, randomized, active-controlled EPIK-O/ENGOT-OV61 trial investigating alpelisib in combination with olaparib compared with standard-of-care chemotherapy in patients with platinum-resistant or -refractory HGSOC with no germline BRCA mutation. Progression-free survival (blinded independent review committee) is the primary end point. Overall survival is a key secondary end point.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Glasspool, Dr Rosalind |
Authors: | Konstantinopoulos, P. A., Gonzalez-Martin, A., Cruz, F. M., Friedlander, M., Glasspool, R., Lorusso, D., Marth, C., Monk, B. J., Kim, J.-W., Hinson, P., Ajipa, O., Pretre, V., Han, Y., and Matulonis, U. A. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Future Oncology |
Publisher: | Future Medicine |
ISSN: | 1479-6694 |
ISSN (Online): | 1744-8301 |
Published Online: | 06 September 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in Future Oncology 18(31): 3481-3492 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record